The Biotechnology Innovation Organization (BIO) recently expressed its support of the Industry Declaration on Combating Antimicrobial Resistance, which was signed by 85 diagnostic and biopharmaceutical companies.
"Antimicrobial resistance is an urgent public health issue, requiring comprehensive cooperation between all stakeholders -- including governments, industry and health care providers -- to properly address," BIO President and CEO Jim Greenwood said. "Today's Declaration on Combating Antimicrobial Resistance underscores our industry's commitment to reducing the development of antimicrobial resistance, investing in R&D of novel products to prevent, diagnose and treat resistant infections, as well as improving access to new and existing antibiotics and vaccines for all patients."
The declaration was released earlier this week at the World Economic Forum in Switzerland.
"We echo the declaration's call for governments and payers to create a sustainable and predictable market that supports innovation and investment in the development of new products to combat antimicrobial resistance, while also maintaining safeguards for their appropriate use," Greenwood said. "To accomplish these critical goals, the value assigned to antibiotics, diagnostics, vaccines and other novel products addressing antimicrobial resistance should reflect the benefits they bring to society and the investment required for their creation."
